GlassScriptPhysician profile
Shelley J Jones
NPI 1598752800
$1,607.47
in general payments reported to CMS, 2019-2025
19 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $79.35 · 2021: $290 · 2022: $122 · 2023: $221 · 2024: $408 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830 · Consulting Fee: $18.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.50 |
| Consulting Fee | $18.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $359.57 | 2019-2024 | Arikayce |
| Abbvie INC. | $301.53 | 2021-2025 | |
| Melinta Therapeutics, LLC | $179.98 | 2019-2024 | Kimyrsa, Vabomere, Rezzayo |
| Paratek Pharmaceuticals, INC. | $124.09 | 2023-2025 | Nuzyra |
| Hospira, INC. | $91.73 | 2024-2025 | |
| Gilead Sciences, INC. | $80.72 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $76.90 | 2024 | |
| Allergan, INC. | $56.69 | 2019-2020 | |
| Viiv Healthcare Company | $56.64 | 2019-2023 | Cabenuva |
| Pfizer INC. | $49.73 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $41.72 | 2019-2025 | Pifeltro, Capvaxive |
| Adma Biomanufacturing LLC | $38.57 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $30.80 | 2022-2023 | Evusheld |
| Mayne Pharma Commercial LLC | $28.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.53 | 2024 | Hyqvia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $19.74 | 2019 | |
| Integra Lifesciences Corporation | $19.56 | 2019 | |
| Shionogi INC | $17.10 | 2022 | |
| Shire North American Group INC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.